Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype

BACKGROUND: Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves maximal surgical resection of the tumor followed by radiation and chemotherapy (temozolomide [TMZ]). The 5-year survival rate of patients with GBM is <10%, a co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Teng, Jian, Hejazi, Seyedali, Hiddingh, Lotte, Carvalho, Litia, de Gooijer, Mark C, Wakimoto, Hiroaki, Barazas, Marco, Tannous, Marie, Chi, Andrew S, Noske, David P, Wesseling, Pieter, Wurdinger, Thomas, Batchelor, Tracy T, Tannous, Bakhos A
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892145/
https://ncbi.nlm.nih.gov/pubmed/29099956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox198
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados